Prognostic and predictive role of immune microenvironment in colorectal cancer

Table 1 Studies of immunoscore role in patients receiving adjuvant chemotherapy

Ref.	CRC stage	ACT	IS predictive role (DFS)
Church et al[27]	III	mFOLFOX, 3 vs 6 months	3-yr DFS: 3 months IS high/IS low HR = 1.80 (95%CI: 1.25-2.60); 6 months IS high/IS low HR = 2.00 (95%CI: 1.38-2.92)
Pagès et al[28]	III	mFOLFOX, 3 vs 6 months	DFS: IS Int + high: HR = 0.53; 95%CI: 0.37-0.75; P = 0.0004; IS low: HR = 0.84, P = 0.269
Mlecnik et al[29]	II, III	5-FU	IS 2-3 III stage: HR = 2.69 (1.02-7.11) P = 0.038; IS 2-3 II: HR = 1.47 (0.35-6.18) P: Non-significant; IS4/IS0-1: No effect of ACT was detected
Pagès et al[30]	III	mFOLFOX, 3 vs 6 months	3-yr DFS: T1-3, N1, IS high 91.4% vs 80.9%, P = 0.01; T1-3, N1, IS low 77.5% vs 74.5%, P = 0.56; T4/N2 IS high 72.0% vs 56.0%, P = 0.006; T4/N2 IS low 58.2% vs 52.6%, P = 0.2

ACT: Adjuvant chemotherapy; CI: Confidence interval; CRC: Colorectal cancer; DFS: Disease-free survival; HR: Hazard ratio; IS: Immunoscore.

Table 2 Studies of immunoscore in different tumor types

Ref.	Tumor	Number of patients, n	Test	Result
Ghiringhelli et al[69], 2023	NSCLC	133	IS-IC	Correlation IS and PFS (HR = 0.39, 95%CI: 0.26-0.59, P < 0.0001), OS (HR = 0.42, 95%CI: 0.27-0.65, P < 0.0001). 36-month PFS IS-high 34%, IS-low 0%
Antoniotti et al[65], 2022	CRC	216	IS-IC	IS-high + ICI - OS HR = 0.39, 95%CI: 0.18-0.84, P < 0.001
Bifulco et al[70], 2014	Melanoma	190	IS-IC	Correlation CD8+, PD-L1- and OS P = 0.04

CI: Confidence interval; CRC: Colorectal cancer; HR: Hazard ratio; ICI: Immune checkpoint inhibitor; IS: Immunoscore; NSCLC: Non-small cell lung cancer; OS: Overall survival; PD-L1: Programmed cell death-ligand 1; PFS: Progression-free survival.